Application No.: 10/688,059

Reply to Office action of July 17, 2006

RECEIVED CENTRAL FAX CENTER UCT 1 3 2006

## Amendments to the Claims:

Please add New Claims 2-19.

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

- 1. (Currently Amended) A composition for the sustained release of <u>a</u> biologically active polypeptide <u>consisting essentially of emprising</u>: a biocompatible <u>polylactide-co-glycolide</u> polymer having dispersed therein a biologically active polypeptide, a sugar and glycine.
- 2. (New) The composition of claim 1, wherein the glucoregulatory peptide is selected from GLP-1, GLP-2, exendin-3, exendin-4 or a combination thereof.
- 3. (New) The composition of claim 2, wherein the biologically active polypeptide is present from about 0.01% (w/w) to about 50% (w/w) of the total weight of the composition.
- 4. (New) The sustained release composition of claim 3, wherein the biologically active polypeptide is present in a range from about 0.1% (w/w) to about 30% (w/w) of the total weight of the composition.
- 5. (New) The composition of claim 4, wherein the polypeptide is present from about 0.1% (w/w) to about 10% (w/w) of the total weight of the sustained release composition.
- 6. (New) The composition of claim 5, wherein the polypeptide is present from about 0.5% (w/w) to about 5% (w/w) of the total weight of the sustained release composition.
- 7. (New) The composition of claim 1, wherein the sugar is present from about 0.01% to about 50% w/w of the total weight of the sustained release composition.

Application No.: 10/688,059

Reply to Office action of July 17, 2006

- 8. (New) The composition of claim 7, wherein the sugar is present from about 0.01% to about 10% w/w of the total weight of the sustained release composition.
- 9. (New) The composition of claim 8, wherein the sugar is present from about 0.1% to about 5% w/w of the total weight of the sustained release composition.
- 10. (New) The composition of claim 1, wherein the sugar is selected from a monosaccharide, a disaccharide, a sugar alcohol or a combination thereof.
- 11. (New) The composition of claim 10, wherein the sugar is selected from sucrose, trehalose, mannitol and combinations thereof.
- 12. (New) The composition of claim 11, wherein the sugar is a disaccharide.
- 13. (New) The sustained release composition of claim 12, wherein the disaccharide is sucrose, trehalose or a combination thereof.
- 14. (New) A composition for the sustained release of biologically active polypeptide consisting essentially of: a biocompatible polymer having dispersed therein exendin-4, sucrose and glycine.
- 15. (New) The composition of claim 14, wherein the biocompatible polymer is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, poly(lactic acid-co-glycolic acid)s and blends and copolymers thereof.
- 16. (New) The composition of claim 15, wherein the sucrose is present at a concentration from about 0.01% w/w to about 10% w/w of the total weight of the sustained release composition.

Application No.: 10/688,059

Reply to Office action of July 17, 2006

- 17. (New) The composition of claim 15, wherein the exendin-4 is present at a concentration of about 0.1% to about 10% of the total weight of the composition.
- 18. (New) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 1.
- 19. (New) A method of treating a patient suffering from Type 2 diabetes comprising administering a therapeutically effective amount of a sustained release composition according to claim 14.